Skip to content
Back to explorer
Printable monograph

Tumor-infiltrating lymphocyte (TIL) therapy

Lifileucel

Amtagvi · LIFI

Tumor-infiltrating lymphocyte (TIL) therapy · approved 2024 · 6 citations · FAERS AKI reporting ROR 8.22 (95% CI 5.37–12.58, 23 AKI reports)

Up to date· through 2025
Fairly sourced6/9 · 6 signals
  • Met: 6 citations
  • Not met: 12+ references
  • Not met: Accrued over 10+ years (span: 7y)
  • Met: Beyond single case reports
  • Met: High-impact journal
  • Met: Landmark reference
  • Met: Current through 2025
  • Met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A one-time tumor-infiltrating-lymphocyte product whose kidney risk lives in the IL-2 conditioning, not the cells.

ModerateTumor-infiltrating lymphocyte (TIL) cell therapy
Unresectable or metastatic melanoma (post anti-PD-1)

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Not in the atlas's table of label-specified renal dose changes; the Dosing section has the full entry.
Hemodialysis
Not removed by hemodialysis
The one-time TIL cell product is not dialyzable and needs no renal dose change; the renal levers are the conditioning regimen — fludarabine (renally cleared, active metabolite partly dialyzable, requires dose reduction in renal impairment) and hemodynamically-titrated high-dose IL-2.
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
Yes
Label: AMTAGVI, Oct 2025. Not necessarily about the kidney. FDA label section.
§01

Signature kidney injury

AKI is common in the overall regimen but is driven by the high-dose IL-2 component (and lymphodepletion), not the TILs themselves. In the pooled C-144-01 experience renal/AKI events fell within the expected high-dose IL-2 toxicity spectrum; a clean drug-specific AKI rate for the TIL product alone is not established. By analogy to other adoptive cell therapies, AKI in the broader CAR-T literature runs 5-33%.Source: Chesney et al., J Immunother Cancer 2022

Onset & rechallenge

Time to injuryAcute (~1–7 days)

Within hours to days of the high-dose IL-2 given during conditioning/expansion.

Distilled from: “Acute — within hours to days of high-dose IL-2 administration during the conditioning/expansion phase.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. Prerenal / Hemodynamic AKI#1 · Signaturequalitative — no citable incidence

    Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

  2. Acute Tubular NecrosisSecondaryqualitative — no citable incidence

    Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.

  3. Electrolyte DisturbanceSecondaryqualitative — no citable incidence

    Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

Incidence not quantified
SeverityModerate
ReversibilityReversible
Evidence6 citations
Nephron map

Functional / pre-renal — reduced perfusion upstream of the nephron; no single structural segment is injured.

Prerenal / Hemodynamic AKI: functional / pre-renal, no single structural segment injured.

Vasculature / Endothelium — not involved
Proximal Tubule — not involved
Distal Tubule / Collecting Duct — not involved

Prerenal / Hemodynamic AKI

Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

§03

Kidney injury

Mechanism of kidney injury

High-dose IL-2 causes a systemic capillary-leak syndrome: cytokine-mediated vascular endothelial permeability produces intravascular volume depletion, hypotension and prerenal hemodynamic AKI that can progress to ischemic acute tubular necrosis. Lymphodepleting fludarabine/cyclophosphamide adds direct tubular and prerenal stress; rapid tumor kill can trigger tumor-lysis metabolic derangements; cytokine release and sepsis from neutropenia contribute additional ischemic injury.

Clinical presentation

Oliguria, weight gain and edema with hypotension during IL-2 dosing; rising creatinine, low fractional excretion of sodium early (prerenal) evolving to ATN with muddy-brown granular casts if ischemia persists; electrolyte derangements and, with tumor lysis, hyperuricemia/hyperphosphatemia/hyperkalemia.

Management

Supportive intensive care: judicious fluids and vasopressors for capillary-leak hypotension, hold further IL-2 doses, treat ischemic ATN supportively, and apply standard tumor-lysis measures if metabolic derangements appear. AKI is usually reversible as IL-2 effects resolve; renal replacement therapy is rarely needed.Lesion-level management framework

Risk factors

  • Number/intensity of high-dose IL-2 doses tolerated
  • Capillary-leak-driven hypotension
  • Baseline CKD, older age, cardiovascular disease
  • Lymphodepleting fludarabine/cyclophosphamide and nephrotoxic antimicrobials

Prevention

  • Treat only in centers experienced with high-dose IL-2
  • Careful fluid and pressor management during capillary leak
  • Stop IL-2 doses for evolving organ dysfunction
  • Tumor-lysis prophylaxis through conditioning
Anticancer mechanism· how it treats cancer

Autologous tumor-infiltrating lymphocytes (TILs) expanded ex vivo and reinfused after non-myeloablative lymphodepletion (fludarabine/cyclophosphamide), followed by high-dose bolus interleukin-2 (IL-2) to support TIL persistence. Approved for advanced melanoma after progression on a PD-1 inhibitor (and BRAF-targeted therapy if BRAF-mutant).

Note · Class/regimen-based reasoning; the immunotherapy and CAR-T nephrotoxicity reviews are cited for the IL-2/cell-therapy mechanisms.
§04

Clinical depth

Renal dose adjustment

Lifileucel itself is a one-time cell infusion with no renal dose adjustment. The renal-relevant levers are the conditioning regimen: fludarabine requires dose reduction in renal impairment (it is renally cleared and accumulates), and high-dose IL-2 dosing is governed by real-time hemodynamic/organ tolerance rather than a fixed CrCl threshold.

Dialyzability & ESKD dosing

The TIL product is not dialyzable. Among conditioning agents, fludarabine's active metabolite is partly dialyzable but timing is not standardized; IL-2 management is hemodynamic. No established protocol exists for the regimen in dialysis-dependent patients, who are generally excluded.

Differential diagnosis

Separate IL-2 capillary-leak prerenal AKI / ATN (hypotension, edema) from tumor-lysis AKI (urate/phosphate, early), fludarabine tubular effect, and neutropenic-sepsis ATN. The pattern and timing relative to IL-2 dosing usually identify the dominant mechanism.

Monitoring

  • Hourly-to-daily creatinine, urine output and weight during IL-2
  • Blood pressure and volume status (capillary leak surveillance)
  • Electrolytes, uric acid and phosphate (tumor-lysis screen) at conditioning
  • Markers of neutropenic sepsis as a competing AKI cause

Key trials & series

  • C-144-01 pooled cohorts (Chesney, J Immunother Cancer 2022) — registrational safety dataset
  • Sarnaik JCO 2021 — initial efficacy/safety report describing the IL-2 regimen

Clinical pearls

  • The kidney risk is the regimen (high-dose IL-2 + lymphodepletion), not the TIL cells.
  • IL-2 AKI is the textbook capillary-leak prerenal-to-ATN sequence and is usually reversible if IL-2 is stopped.
  • Don't forget to renally dose-reduce fludarabine — it accumulates and adds tubular toxicity.
§05

References

6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

6 references · 2018–2025 · 3 since 2023
202018: 1 citation2021: 1 citation2022: 1 citation2024: 2 citations2025: 1 citation201820202025

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.LandmarkLifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.Sarnaik AA et al. · J Clin Oncol · 2021 · PMID 33979178Key efficacy/safety report; describes the high-dose IL-2 regimen that drives the hemodynamic AKI risk.
  2. 2.Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.Chesney J et al. · J Immunother Cancer · 2022 · PMID 36600653Pooled safety analysis; renal/AKI events appear within the expected high-dose IL-2 toxicity spectrum.
  3. 3.LandmarkNephrotoxicity of Cancer Immunotherapies: Past, Present and Future.Perazella MA et al. · J Am Soc Nephrol · 2018 · PMID 29959196Onconephrology review covering high-dose IL-2 capillary-leak AKI — the mechanistic basis for the conditioning-related renal risk.
  4. 4.Acute kidney injury following CAR-T cell therapy: a nephrologist's perspective.Kanbay M et al. · Clin Kidney J · 2024 · PMID 39781479Nephrology review of adoptive cell-therapy AKI (incidence 5-33%, CRS/TLS/lymphodepletion mechanisms) — directly analogous to TIL therapy.
  5. 5.Nephrotoxicity in CAR-T Cell Therapy.Sadowski K et al. · Transplant Cell Ther · 2025 · PMID 40107382Reviews AKI/CKD mechanisms, risk factors and lymphodepletion safety in cell therapy — supports the conditioning-driven renal framing.
  6. 6.Tumour lysis syndrome.Howard SC et al. · Nat Rev Dis Primers · 2024 · PMID 39174582Authoritative TLS review supporting the tumor-lysis component of cell-therapy-associated AKI.
FDA label — boxed warning & renal dosing· boxed warning

Quoted verbatim from this agent's current FDA label (Oct 2025) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING: TREATMENT-RELATED MORTALITY, PROLONGED SEVERE CYTOPENIA, SEVERE INFECTION, CARDIOPULMONARY and RENAL IMPAIRMENT Monitor patients for prolonged severe cytopenia and monitor for internal organ hemorrhage [see Warnings and Precautions (5.1 , 5.2 , 5.3) ]. Administer filgrastim or a biosimilar product to patients beginning Day 1 after AMTAGVI and continuing daily until the absolute neutrophil count (ANC) is greater than 1000 per mm 3 for 3 consecutive days, or per institutional standard. Treat severe infections [see Warnings and Precautions (5.1 , 5.4) ]. Monitor cardiopulmonary and renal functions throughout the treatment course. [see Warnings and Precautions (5.1 , 5.5 , 5.6 , 5.7) ]. Administer in an inpatient hospital setting. An intensive care facility and specialists skilled in cardiopulmonary or intensive care medicine must be available [see Dosage and Administration (2.1) , and Adverse Reactions (6.1) ] . WARNING: TREATMENT-RELATED MORTALITY, PROLONGED SEVERE CYTOPENIA, SEVERE INFECTION, CARDIOPULMONARY and RENAL IMPAIRMENT See full prescribing information for complete boxed warning. Monitor patients for prolonged severe cytopenia and monitor for internal organ hemorrhage ( 5.1 , 5.2 , 5.3 ) Treat severe infections ( 5.1 , 5.4 ) Monitor cardiopulmonary and renal functions throughout the treatment course ( 5.1 , 5.5 , 5.6 , 5.7 ) Administer in an inpatient hospital…

Kidney rows of the label's dosage tables

None of the newest openFDA labels for this product carries a dosage table. The label's prose can still give kidney instructions.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 285 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
  • Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS reported renal phenotypes· 3 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.

What reporting says about this profile's documented lesions

  • Electrolyte Disturbancereporting signal · ROR 3.94 — but the naming terms alone are not disproportionate, so this rests on terms merely consistent with the lesion
  • Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
  • Acute Tubular NecrosisNot measurable in reporting — Reporters cannot reliably name this lesion, so its absence from FAERS is expected and is not evidence against the documented injury.
Thrombotic Microangiopathy
ROR 12.7695% CI 4.09–39.82· 3 reports· IC025 0.20
SIADH / Hyponatremia
ROR 6.8295% CI 3.38–13.77· 8 reports· IC025 1.15
Electrolyte Disturbance
ROR 3.9495% CI 2.16–7.21· 11 reports· IC025 0.79
FAERS outcomes & reporting trend· 20.4% of reports w/ death · 51.6% w/ hospitalization
20.4%

Reported with a death outcome

58 of 285 reports

51.6%

Reported with hospitalization

147 of 285 reports

Reports per year

  • 2015: 0 reports
  • 2016: 0 reports
  • 2017: 0 reports
  • 2018: 0 reports
  • 2019: 0 reports
  • 2020: 9 reports
  • 2021: 7 reports
  • 2022: 10 reports
  • 2023: 10 reports
  • 2024: 61 reports
  • 2025: 121 reports
  • 2026: 67 reports

Reports received per year, 2015–2026 · most recent year is partial.

FAERS adverse-event signal — all organ systems· 10 systems · 285 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.

Disproportionality (acute kidney injury):ROR 8.2295% CI 5.37–12.58· 23 AKI reports· IC025 2.09·AKI is reported disproportionately more often than for other drugs (CI entirely above 1) — a hypothesis-generating signal, not proof of causation.
Renal & urinary
Acute Kidney Injury23
General / constitutional
Pyrexia45Chills26Malaise14Fatigue12Multiple Organ Dysfunction Syndrome12
Respiratory
Hypoxia23Pleural Effusion16Respiratory Failure15Dyspnoea14Acute Respiratory Failure11
Blood & lymphatic
Febrile Neutropenia19Pancytopenia18Thrombocytopenia17Anaemia14Cytopenia10
Gastrointestinal
Nausea16Diarrhoea13Vomiting11
Vascular
Hypotension32
Cardiac
Tachycardia15Atrial Fibrillation14
Psychiatric
Mental Status Changes13Confusional State11
Immune / infection
Cytokine Release Syndrome20
Skin
Rash16
Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Lifileucel sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Arsenic trioxide

Trisenox · Differentiating agent

Profile

Differentiation syndrome; QT prolongation.

PREATNLYTE
Moderate#1 · 85% phenotype match

Enasidenib

Idhifa · IDH2 inhibitor

Profile

Differentiation syndrome and tumor lysis.

PREATNLYTE
Moderate#2 · 85% phenotype match

Ivosidenib

Tibsovo · IDH1 inhibitor

Profile

Differentiation syndrome → AKI; tumor lysis.

PRELYTEATN
Moderate#3 · 85% phenotype match

Afamitresgene autoleucel (Afami-cel)

Tecelra · MAGE-A4 TCR-T cell therapy

Profile

First TCR-T cell therapy for a solid tumor; CRS-associated hemodynamic AKI.

PRELYTE
Moderate#4 · 84% phenotype match

Ziftomenib

Komzifti · Menin inhibitor

Profile

2025 NPM1-mutated AML menin inhibitor; differentiation syndrome and tumor lysis.

PRELYTE
Moderate#5 · 84% phenotype match

Mobocertinib

Exkivity · EGFR exon20 TKI

Profile

Diarrhea-driven prerenal AKI; QT prolongation.

PREATNLYTE
Mild#6 · 83% phenotype match
Compare Lifileucel with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.